tbuckley/cabot-search huggingface dataset:
Abstract 5156: The roles of x-linked Midline 1 interacting protein 1 (MID1IP1) in gender disparity and development of hepatocellular carcinoma
Authors: Elley Yung Tuen Chiu, Irene Oi Lin Ng.
Journal: Cancer Research (2016)

Abstract HBV-associated hepatocellular carcinoma (HCC) has a male predominance, with a male-to-female ratio of about 5:1, suggesting gender difference is one of the major risk factors for HCC development. However, up till now, no concrete evidence is obtained to elucidate the male predominance of HCC. It is believed that the gender-specific signaling pathway is critically involved and targeting this pathway may provide a significant treatment outcome. To target candidates that are implicated in the male predominance in HCC, aberrant expression of sex-linked genes between HCC tumors and non-tumorous livers (NT-L) draws particular attention. Previously, we performed transcriptome sequencing on sixteen pairs of human HCC tumors and NT-Ls. Our preliminary data show that a potential target, Midline 1 interacting protein 1 (MID1IP1) which is involved in hepatic lipogenesis and microtubule stabilization, was remarkably overexpressed in HCC tumors as compared to the NT-Ls (fold change = 2.73; p = 0.017). Moreover, the expression of MID1IP1 was significantly higher in male non-tumorous liver tissue than that of female (fold change = 2.63; p = 0.001). In addition, the upregulation of MID1IP1 correlated with less tumor encapsulation, more tumor microsatellite formation, more venous and direct liver invasion, and poorer tumor stage, features of a more aggressive biological behavior in our clinicopathological correlation study. Moreover, upregulation of MID1IP1 in the tumors was associated with a poorer overall survival. In its functional study, upon knockdown of MID1IP1, HCC cells (BEL7402, SMMC7721 and HepG2) had reduced proliferation rates in the cell proliferation assay and colony formation assay. Here, we also showed that the migratory abilities of the HCC cell lines with MID1IP1 knockdown were remarkably reduced in the transwell assay. Furthermore, the STRING interaction network analysis suggests that MID1IP1 interacts with Suppressor of Fused (Sufu), which is a regulator of Gli in the hedgehog (HH) pathway. To examine its regulatory pathway, we showed that the mRNA expression of the negative regulator of HH pathway, Gli3, was increased in the MID1IP1 knockdown HCC cells. The downstream target of Gli, cyclin D, was also downregulated upon MID1IP1 knockdown. In summary, our data suggest that the MID1IP1 plays a significant role in the male predominance of human HCC. MID1IP1 may also play a novel role in the regulation of hedgehog signaling. Citation Format: Elley Yung Tuen Chiu, Irene Oi Lin Ng. The roles of x-linked Midline 1 interacting protein 1 (MID1IP1) in gender disparity and development of hepatocellular carcinoma. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 5156.
The effect of early palliative care on end-of-life ICU utilization and ICU course in patients with advanced cancer.
Authors: Andrew Michael Romano, Kristine E Gade, Gradon Nielsen, Robert Havard, James A Harrison, Josh Barclay, George J. Stukenborg, Paul W Read, Leslie J Blackhall, Patrick Michael Dillon
Journal: Journal of Clinical Oncology (2016)

e21704 Background: Early palliative care for advanced cancer patients has been demonstrated to yield improvements in quality of life and survival, but less is known about its impact on ICU utilization at the end of life. This study aims to assess the impact of a comprehensive early palliative care program on ICU utilization and other related outcomes among patients with advanced cancer. Methods: Cases were composed of retrospective cohort of patients with advanced cancer enrolled in an early, multi-disciplinary outpatient palliative care intervention program utilizing end of life care planning, interdisciplinary meetings and patient reported outcomes assessment integrated within the electronic medical record (n = 275). Those were compared with a concurrent control group of patients receiving standard care over the same time period (n = 195) at a single institution, university hospital with multivariable logistic regression analysis. Main outcome measures included ICU admission, death in hospital, death in ICU, enrollment in hospice, receipt of chemotherapy, and receipt of radiation within last months of life. Secondary analyses assessed details of ICU admission including procedures, disposition and code status. Results: Patients receiving standard care had significantly higher likelihood of ICU admission at the end of life (last 6 months, OR = 3.07, p < 0.001; last month, OR = 3.59, p < 0.001; terminal admission OR = 4.69, p < 0.0001), higher likelihood of death in hospital (OR = 4.14, p < 0.001) or in ICU (OR = 5.57, p < 0.001), and lower likelihood of hospice enrollment (OR = 0.13, p < 0.001). No significant differences in utilization of chemotherapy or radiation occurred between the compared patient groups. There were no differences between groups in length of ICU stay, code status, procedures performed in ICU, disposition location, and outcomes following ICU admission Conclusions: Early palliative care significantly reduces ICU utilization at the end of life, but does not change ICU events. This study supports early initiation of palliative care for advanced cancer patients, prior to hospitalizations and intensive care.
Abstract LB-088: Heterodimeric IL-15 enhances tumor infiltration, persistence and effector functions of adoptively transferred tumor-specific T cells in the absence of lymphodepletion
Authors: Sinnie Ng, Cristina Bergamaschi, Bethany Nagy, Candido Alicea, Shawn M. Jensen, Bernard A. Fox, Barbara K. Felber, George N. Pavlakis
Journal: Cancer Research (2016)

Abstract Adoptive cell transfer (ACT) is a promising immunotherapeutic approach for cancer. Lymphodepletion of the host is associated with favorable ACT outcomes but it may cause detrimental effects in humans. Lymphodepletion results in high level of homeostatic cytokines including Interleukin-15 (IL-15) that support survival and proliferation of the transferred lymphocytes. We tested the hypothesis that exogenous IL-15 enhances ACT in the absence of lymphodepletion. We have previously shown that bioactive IL-15 in vivo comprises a stable complex of the IL-15 chain with the IL-15 Receptor alpha chain, termed heterodimeric IL-15 (hetIL-15). We therefore evaluated the effects of the combination regimen ACT+hetIL-15 in absence of lymphodepletion by transferring melanoma-specific Pmel-1 T cells into B16 melanoma-bearing mice. hetIL-15 promoted infiltration and persistence of both adoptively transferred Pmel-1 cells and endogenous CD8+ T cells in the tumor. Following lymphodepletion by irradiation, Pmel-1 cells also localized to tumor sites efficiently, but their persistence was severely reduced in comparison to mice treated with hetIL-15. Importantly, we found that hetIL-15 preferentially enriched Pmel-1 cells in the tumor sites. hetIL-15 treatment also supported proliferation and cytotoxic function of tumor-infiltrating Pmel-1 cells, while reducing their expression level of PD-1, and resulted in improved tumor control and survival benefit. Thus, hetIL-15 administration improves the outcome of ACT in non-lymphodepleted hosts, and can be a valuable addition to strategies for cancer immunotherapy. Citation Format: Sinnie Ng, Cristina Bergamaschi, Bethany Nagy, Candido Alicea, Shawn M. Jensen, Bernard A. Fox, Barbara K. Felber, George N. Pavlakis. Heterodimeric IL-15 enhances tumor infiltration, persistence and effector functions of adoptively transferred tumor-specific T cells in the absence of lymphodepletion. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr LB-088.
Safety and Efficacy of a Combination of Imatinib and Pegylated Interferon α2a (Pegasys®) in Newly Diagnosed Patients with Chronic Myelogenous Leukemia - A Phase II Cohort Study.
Authors: Andreas Hochhaus, A. Neubauer, M.C. Mueller, T. Fischer, C. Waller, T.H. Bruemmendorf, T. Bostel, C. Lengerke, R. Hehlmann, A. Burchert
Journal: Blood (2007)
Individualized administration of capecitabine plus lapatinib in heavily pretreated HER2+ metastatic breast cancer patients: A single-center experience.
Authors: P. Papaldo, G. Metro, A. Felici, M. Russillo, D. Pellegrini, A. Fabi, G. Ferretti, M. Introna, F. Cognetti
Journal: Journal of Clinical Oncology (2010)

1108 Background: In the Lapatinib Expanded Access Program (LEAP) the eligibility criteria and the dose of given drugs resembled that used in the phase III EGF 100151 study, with the exception that patients (pts) previously exposed to capecitabine and pts with a PS > 2 could be included as well. Methods: Pts with HER2 3+ staining by IHC or 2+ with gene amplification by FISH as determined locally were admitted. Disease assessment was performed using RECIST criteria. Results: The characteristics of the 54 pts accrued at the Regina Elena Cancer Institute compared with those of the EGF 100151 study were: metastatic sites 3, 48% vs. 48%; 2 sites, 43% vs. 33%; 1 site, 9% vs. 19%; median duration of previous trastuzumab: 83 vs. 42 weeks. Moreover, in our series 31 (42%) pts had received more than 2 lines of chemotherapy for metastatic disease and 14 (26%) pts had received prior capecitabine. In addition, 28 (52%) pts had brain metastases at baseline. Efficacy end points of our 54 pts vs. those enrolled in the EGF 100151 study and its update are shown below (Table). The most common G3 toxicities were: hand-food syndrome (11%), diarrhea (2%), asthenia (6%), neutropenia (4%); drop in the LVEF > 20% in 1 (2%) pt. The median number of capecitabine cycles administered was 6. Cycles of capecitabine were delayed in 23 pts (42%). Capecitabine dose was reduced in 13 (25%) pts (from the first cycle in 9% of pts). In 23 cycles (6%) it was reduced by 25%, whereas in 36 cycles (10%) it was reduced more than 25%. Lapatinib was temporarily interrupted in 9 (17%) pts. Conclusions: In heavily pretreated HER2+ metastatic breast cancer pts treated with capecitabine plus lapatinib, individualized administration following dose reductions/delays for toxicity results in similar OR and TTP but longer clinical benefit compared with EGF 100151 study. TLap+Cap (163 pts) (N Eng J Med 2006) Lap+Cap (163 pts) (Breast Ca Res Tr 08) Regina Elena (54 pts) Median TTP (months) 5.9 8.4 (independent assessment) 6.2 5.9 OR 22% 23.7% 31% PR 21% 23% 26% SD 38% 46% Clinical benefit 27% 29.3% 54% No significant financial relationships to disclose.
Abstract 3635: Performance of the Agilent D5000 and high sensitivity D5000 ScreenTape assays for the Agilent 4200 TapeStation system
Authors: Rainer Nitsche, Lidia Prieto-Lafuente, Claire MacDonald, Isabell Pechtl
Journal: Cancer Research (2016)

Abstract The Agilent 4200 TapeStation system provides automated, fast, and reliable DNA and RNA electrophoresis for up to 96 samples using prepackaged reagents and minimal manual handling. The Agilent D5000 ScreenTape and High Sensitivity D5000 ScreenTape assays have been developed for the separation and analysis of DNA fragments from 100 bp to 5,000 bp, a size range that complements and resides between the Agilent D1000 ScreenTape and the Genomic DNA ScreenTape assays. The 4200 TapeStation system and the DNA ScreenTape assays can be used at several steps of the Next Generation Sequencing (NGS) workflow. With the emergence of methodologies, such as the use of Transposomes, NGS library sizes are tending to increase beyond 1,000 bp, even for the short-read NGS technologies. This Poster focuses on the performance of both D5000 ScreenTape assays with respect to the accuracy and precision of quantification and sizing, as well as the sensitivity of these assays. Data analysis for quantification and molarity determination was compared against the corresponding assay for the Agilent 2100 Bioanalyzer system. Additionally, performance of both the D5000 and High Sensitivity D5000 assays on the 4200 TapeStation was compared to the 2200 TapeStation system. Citation Format: Rainer Nitsche, Lidia Prieto-Lafuente, Claire MacDonald, Isabell Pechtl. Performance of the Agilent D5000 and high sensitivity D5000 ScreenTape assays for the Agilent 4200 TapeStation system. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3635.
Surveillance des maladies transmissibles chez les réfugiés kosovars en Albanie, avril-juin 1999
Authors: M Valenciano, A Pinto, D Coulombier, E Hashorva, M Murthi
Journal: Eurosurveillance (1999)

L’Albanie, dont la population compte 3,5 millions d’habitants, est confrontee a une crise economique et sociale. Le revenu moyen par habitant s’eleve a moins de 1000 US$ par an et, depuis 1995, le chomage a augmente de 2,7% (1). La pauvrete et la migration constituent les problemes de societe majeurs. Le pays est decoupe en 37 districts administratifs. Les soins de sante primaires sont dispenses par un reseau compose de 1500 infirmeries (animees par des infirmieres et des sages-femmes) et de 602 centres de sante (animes par des medecins generalistes). Cinquante-trois polycliniques, 34 hopitaux de district et 10 centres hospitaliers regionaux assurent les soins de sante secondaires. Les soins tertiaires sont dispenses par le seul Centre Hospitalier Universitaire, a Tirana (2). Le systeme de surveillance national de routine porte sur 73 maladies : les centres de sante et les infirmeries transmettent les declarations aux epidemiologistes des districts qui, chaque mois, envoient les informations a l’Institut de Sante Publique (IPH) a Tirana. La qualite de la surveillance est limitee par la fiabilite des donnees, la sous-declaration, la qualite des donnees, leur transmission et les retours d’information (3).
Non-Specific Hemostatic Agents (PCC, aPCC, rVIIa) for Reversal of Direct Oral Anticoagulant Effect in Patients with Major Bleeding Complications: A Retrospective Review
Authors: Deborah M. Siegal, Ron Movilla, Reda Siddiqui, Rebecca Barty, Mark A. Crowther, Nancy M Heddle
Journal: Blood (2015)
Radiotherapy Deferral in Medulloblastoma
Authors: Arnold C. Paulino, Jerry J. Jaboin
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Treatment of Type 2 Diabetes: From “Guidelines” to “Position Statements” and Back
Authors: Ofri Mosenzon, Rena Pollack, Itamar Raz
Journal: Diabetes Care (2016)

Given the increased prevalence of type 2 diabetes worldwide, most patients are treated by their primary health care team (PHCT). PHCTs need guidance in choosing the best treatment regimen for patients, since the number of glucose-lowering agents (GLAs) is rapidly increasing, as is the amount of clinical data regarding these drugs. The American Diabetes Association/European Association for the Study of Diabetes Position Statement emphasizes the importance of personalized treatment and lists drug efficacy, risk of hypoglycemia, effect on weight, side effects, and cost as important parameters to consider when choosing GLAs. The suggested Israeli guidelines refocus earlier international recommendations from 2012 and 2015, based on emerging data from cardiovascular outcome trials as well as what we believe are important issues for patient care (i.e., durability, hypoglycemia risk, and weight gain).
An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia
Authors: S P Koerner, M C André, J S Leibold, P C Kousis, A Kübler, M Pal, S P Haen, H-J Bühring, L Grosse-Hovest, G Jung, H R Salih
Journal: Leukemia (2016)
Abstract 19058: Role of Agxt2 in Metabolism of Adma in the Settings of Acute Elevation of Systemic Adma Levels
Authors: Roman Rodionov, Jens Martens-Lobenhoffer, SIlke Brilloff, Bernd Hohenstein, Norbert Weiss, Stefanie M Bode-Böger
Journal: Circulation (2013)

Background: Endogenous inhibitor of nitric oxide synthases asymmetric dimethylarginine (ADMA) has been proposed to serve as an independent cardiovascular risk factor. The major pathway of ADMA degradation is hydrolysis catalyzed by dimethylarginine dimethylaminohydrolase (DDAH). ADMA can also be metabolized through a different pathway, by alanine:glyoxylate aminotransferase 2 (AGXT2), with the formation of α-keto-δ-(N,N-dimethylguanidino)valeric acid (DMGV). The goal of this study was to better characterize the role of the AGXT2 pathway in metabolism of ADMA in vivo using a recently developed assay for detection of DMGV in biological samples. Methods: ADMA (250 μmol x kg-1 x d-1) was infused in C57/BL6 mice for 3 days using osmotic minipumps implanted intraperitoneally. We performed bilateral nephrectomy in some of the mice 24 hours before the end of ADMA infusion and sample collection. Measurements of ADMA and DMGV were performed LC-MS/MS. Results: Infusion of ADMA for 3 days resulted in a 3.4 fold increase in plasma and in a 5.2 fold increase in urine ADMA levels. Elevation of ADMA concentration coincided with elevation of plasma and urine DMGV levels (2.9 and 3.9 folds respectively). Bilateral nephrectomy in the mice, which did not undergo ADMA infusion, did not increase plasma ADMA levels, while bilateral nephrectomy in the mice, which underwent ADMA infusion, led to a 1.7 fold increase in plasma ADMA levels and a 17.6 fold increase in DMGV levels. Neither bilateral nephrectomy nor infusion of ADMA for 3 days changed the AGXT2 mRNA levels in the liver. Conclusions: Infusion of ADMA leads to increased flux through the AGXT2 pathway of ADMA metabolism in vivo. The observation that each 1 μmol / mmol creatinine increase in ADMA level in urine leads to about 1 μmol / mmol creatinine increase in urine DMGV level suggests that AGXT2 is a major enzyme regulating ADMA levels in urine. The marked increase in DMGV levels in the mice lacking both kidneys suggests significant extrarenal production of DMGV in addition to absent renal excretion. Lack of increase in plasma ADMA levels after nephrectomy in mice infused with saline suggests that ADMA-metabolyzing ezymes are able to compensate for lack of renal excretion of ADMA in our model.
Infliximab Versus Rabbit Anti-Thymocyte Globulin As a Salvage Treatment For Steroid-Refractory Acute Graft-Versus-Host Disease After Reduced-Intensity Cord Blood Transplantation In Adults
Authors: Kazuya Ishiwata, Hisashi Yamamoto, Kousei Kageyama, Daisuke Kaji, Sachie Wada, Aya Nishida, Hikari Ota, Shinsuke Takagi, Masanori Tsuji, Go Yamamoto, Yuki Asano-Mori, Naoyuki Uchida, Koji Izutsu, Atsushi Wake, Akiko Yoneyama, Shigeyoshi Makino, Shuichi Taniguchi
Journal: Blood (2013)
Recommendations for Blood Pressure Measurement in Humans and Experimental Animals
Authors: Thomas G. Pickering, John E. Hall, Lawrence J. Appel, Bonita E. Falkner, John Graves, Martha N. Hill, Daniel W. Jones, Theodore Kurtz, Sheldon G. Sheps, Edward J. Roccella
Journal: Circulation (2005)

Accurate measurement of blood pressure is essential to classify individuals, to ascertain blood pressure–related risk, and to guide management. The auscultatory technique with a trained observer and mercury sphygmomanometer continues to be the method of choice for measurement in the office, using the first and fifth phases of the Korotkoff sounds, including in pregnant women. The use of mercury is declining, and alternatives are needed. Aneroid devices are suitable, but they require frequent calibration. Hybrid devices that use electronic transducers instead of mercury have promise. The oscillometric method can be used for office measurement, but only devices independently validated according to standard protocols should be used, and individual calibration is recommended. They have the advantage of being able to take multiple measurements. Proper training of observers, positioning of the patient, and selection of cuff size are all essential. It is increasingly recognized that office measurements correlate poorly with blood pressure measured in other settings, and that they can be supplemented by self-measured readings taken with validated devices at home. There is increasing evidence that home readings predict cardiovascular events and are particularly useful for monitoring the effects of treatment. Twenty-four-hour ambulatory monitoring gives a better prediction of risk than office measurements and is useful for diagnosing white-coat hypertension. There is increasing evidence that a failure of blood pressure to fall during the night may be associated with increased risk. In obese patients and children, the use of an appropriate cuff size is of paramount importance.
Abstract 4576: Hepatocyte nuclear factor 4 alpha suppresses cell proliferation and induces cellular senescence and apoptosis in prostate cancer cells
Authors: Zhu WANG, Franky Leung Chan
Journal: Cancer Research (2016)

Abstract Hepatocyte nuclear factor 4α (HNF4α, NR2A1) is a highly conserved member of the nuclear receptor superfamily of ligand-dependent transcription factors. Recent advances show that it is a key transcriptional regulator of many genes, involved in xenobiotic and drug metabolism and also cancers of gastrointestinal tract. However, the exact functional roles of HNF4α gene in prostate cancer progression are still not fully understood. In this study we used the overexpression (gain-of-function) and knockdown (loss-of-function) approaches to determine the functional roles of HNF4α in prostate cancer. Our results showed that HNF4α exhibited a reduced expression pattern in many prostate cancer cells compared to immortalized prostatic cell lines. Its overexpression could significantly inhibit the cell proliferation of prostate cancer cells, and trigger the cellular senescence and apoptosis by activation of p21 signal pathway in a p53-independent manner. We showed that stable overexpression of HNF4α could significantly induce G2/M arrest in PC3 cells, while shRNA-mediated knockdown of HNF4α could induce G1 growth arrest, suggesting that HNF4α might play a negative role in the cell cycle regulation of PC3 cells. Moreover, stable HNF4α knockdown could confer resistance to paclitaxel treatment and enhance colony formation capacity in prostate cancer cells. Together, our results suggest that HNF4α may play a tumor suppressor function in prostate cancer progression.This work was supported by a Direct Grant for Research 2015-2016 (2015. 1. 064), CUHK. Citation Format: Zhu WANG, Franky Leung Chan. Hepatocyte nuclear factor 4 alpha suppresses cell proliferation and induces cellular senescence and apoptosis in prostate cancer cells. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4576.